
Xeris Biopharma Holdings, Inc.: shareholders and insiders
Price
$16.97
November 20, 2026Market cap $3.1B
What Ploutos Investor adds for Xeris Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 30% since Nov 5, 2026, when the 10-Q these figures come from was filed ($13.08 then, $16.97 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 6, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$5.8M
9 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan83%
- The rest17%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $4.6M by 9 people
- 2025: no buys, sold $1.2M by 3 people
- 2026: no buys, sold $4.6M by 9 people
- Nov 5, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Nov 2, 2026Steven PieperChief Financial OfficerKind10b5-1
- Nov 2, 2026Beth HechtChief Legal Officer and Corporate SecretaryKind10b5-1
- Nov 2, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Nov 2, 2026Menassie TaddeseDirectorKind
- Oct 1, 2026Steven PieperChief Financial OfficerKind10b5-1
- Oct 1, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Oct 1, 2026Beth HechtChief Legal Officer and Corporate SecretaryKind10b5-1
- Sep 28, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Sep 1, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Sep 1, 2026Beth HechtChief Legal Officer and Corporate SecretaryKind10b5-1
- Sep 1, 2026Steven PieperChief Financial OfficerKind10b5-1
- Aug 12, 2026Steven PieperChief Financial OfficerKind10b5-1
- Aug 3, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Aug 3, 2026Beth HechtChief Legal Officer and Corporate SecretaryKind10b5-1
- Aug 1, 2026John Patrick Shannon JrChief Executive Officer and Chairman of the BoardKind
- Aug 1, 2026Kevin McCullochPresident and Chief Operating OfficerKind
- Jul 7, 2026Steven PieperChief Financial OfficerKind10b5-1
- Jul 6, 2026Steven PieperChief Financial OfficerKind10b5-1
- Jul 1, 2026Nerissa KreherDirectorKind
- Jul 1, 2026Kevin McCullochPresident and Chief Operating OfficerKind10b5-1
- Jul 1, 2026Beth HechtChief Legal Officer and Corporate SecretaryKind10b5-1
- Jun 4, 2026Garheng KongDirectorKind
- Jun 4, 2026Marla PerskyDirectorKind10b5-1
- Jun 4, 2026Dawn HalkuffDirectorKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 25.0K | $12.49 | $312.2K | Form 4 |
| Nov 2, 2026 | Steven PieperChief Financial Officer | 10b5-1 | 5,000 | $10.23 | $51.2K | Form 4 |
| Nov 2, 2026 | Beth HechtChief Legal Officer and Corporate Secretary | 10b5-1 | 25.0K | $10.23 | $255.8K | Form 4 |
| Nov 2, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 15.0K | $10.23 | $153.5K | Form 4 |
| Nov 2, 2026 | Menassie TaddeseDirector | 22.4K | – | – | Form 4 | |
| Oct 1, 2026 | Steven PieperChief Financial Officer | 10b5-1 | 5,000 | $9.41 | $47.0K | Form 4 |
| Oct 1, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 15.0K | $9.41 | $141.1K | Form 4 |
| Oct 1, 2026 | Beth HechtChief Legal Officer and Corporate Secretary | 10b5-1 | 16.7K | $9.41 | $156.8K | Form 4 |
| Sep 28, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 25.0K | $10.00 | $250.0K | Form 4 |
| Sep 1, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 15.0K | $8.49 | $127.3K | Form 4 |
| Sep 1, 2026 | Beth HechtChief Legal Officer and Corporate Secretary | 10b5-1 | 16.7K | $8.49 | $141.4K | Form 4 |
| Sep 1, 2026 | Steven PieperChief Financial Officer | 10b5-1 | 5,000 | $8.50 | $42.5K | Form 4 |
| Aug 12, 2026 | Steven PieperChief Financial Officer | 10b5-1 | 5,000 | $8.50 | $42.5K | Form 4 |
| Aug 3, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 15.0K | $8.02 | $120.2K | Form 4 |
| Aug 3, 2026 | Beth HechtChief Legal Officer and Corporate Secretary | 10b5-1 | 16.7K | $8.01 | $133.6K | Form 4 |
| Aug 1, 2026 | John Patrick Shannon JrChief Executive Officer and Chairman of the Board | 36.6K | $8.08 | $296.1K | Form 4 | |
| Aug 1, 2026 | Kevin McCullochPresident and Chief Operating Officer | 21.9K | $8.08 | $177.1K | Form 4 | |
| Jul 7, 2026 | Steven PieperChief Financial Officer | 10b5-1 | 27.6K | $8.52 | $235.3K | Form 4 |
| Jul 6, 2026 | Steven PieperChief Financial Officer | 10b5-1 | 17.4K | $8.50 | $147.9K | Form 4 |
| Jul 1, 2026 | Nerissa KreherDirector | 33.6K | – | – | Form 4 | |
| Jul 1, 2026 | Kevin McCullochPresident and Chief Operating Officer | 10b5-1 | 90.0K | $8.03 | $722.5K | Form 4 |
| Jul 1, 2026 | Beth HechtChief Legal Officer and Corporate Secretary | 10b5-1 | 16.7K | $8.03 | $133.9K | Form 4 |
| Jun 4, 2026 | Garheng KongDirector | 24.2K | – | – | Form 4 | |
| Jun 4, 2026 | Marla PerskyDirector | 10b5-1 | 24.2K | – | – | Form 4 |
| Jun 4, 2026 | Dawn HalkuffDirector | 10b5-1 | 20.0K | $6.09 | $121.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by XERS's officers and directors from 2021 up to November 20, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Nobody reports more than 5% today: those who filed have since fallen to 5% or less.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter+2.2%
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-75%
- Millennium Mgmt (Englander)In the quarter+87%
- Renaissance TechnologiesIn the quarter
- AQR CapitalIn the quarter+1.9%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 7.98M | +2.2% | $76M | 0.05% |
| Point72 (Cohen) | 2.13M | $20M | 0.03% | |
| Citadel Advisors (Griffin) | 169.3K | -75% | $1.6M | 0.00% |
| Millennium Mgmt (Englander) | 245.8K | +87% | $2.3M | 0.00% |
| Renaissance Technologies | – | – | 0.00% | |
| AQR Capital | 1.57M | +1.9% | $15M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 4.39% of its shares outstanding were held short, +11.5% since the report before.
- Shares held short
- 8.03M
- 4.39%
- Since the report before7.20M on Sep 30, 2026
- +11.5%
- 3.3
- 2.46M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 38%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 7.79M
- Nov 15, 2023: Shares held short 8.95M
- Nov 30, 2023: Shares held short 8.22M
- Dec 15, 2023: Shares held short 8.12M
- Dec 29, 2023: Shares held short 9.61M
- Jan 12, 2024: Shares held short 10.41M
- Jan 31, 2024: Shares held short 9.40M
- Feb 15, 2024: Shares held short 9.42M
- Feb 29, 2024: Shares held short 9.64M
- Mar 15, 2024: Shares held short 9.24M
- Mar 28, 2024: Shares held short 8.98M
- Apr 15, 2024: Shares held short 8.94M
- Apr 30, 2024: Shares held short 9.64M
- May 15, 2024: Shares held short 10.79M
- May 31, 2024: Shares held short 11.33M
- Jun 14, 2024: Shares held short 11.09M
- Jun 28, 2024: Shares held short 11.00M
- Jul 15, 2024: Shares held short 11.41M
- Jul 31, 2024: Shares held short 11.22M
- Aug 15, 2024: Shares held short 10.81M
- Aug 30, 2024: Shares held short 10.71M
- Sep 13, 2024: Shares held short 11.00M
- Sep 30, 2024: Shares held short 11.09M
- Oct 15, 2024: Shares held short 11.57M
- Oct 31, 2024: Shares held short 11.37M
- Nov 15, 2024: Shares held short 10.15M
- Nov 29, 2024: Shares held short 9.91M
- Dec 13, 2024: Shares held short 9.52M
- Dec 31, 2024: Shares held short 10.19M
- Jan 15, 2025: Shares held short 10.36M
- Jan 31, 2025: Shares held short 10.49M
- Feb 14, 2025: Shares held short 10.27M
- Feb 28, 2025: Shares held short 10.63M
- Mar 14, 2025: Shares held short 11.21M
- Mar 31, 2025: Shares held short 17.04M
- Apr 15, 2025: Shares held short 19.05M
- Apr 30, 2025: Shares held short 17.23M
- May 15, 2025: Shares held short 17.80M
- May 30, 2025: Shares held short 17.60M
- Jun 13, 2025: Shares held short 17.94M
- Jun 30, 2025: Shares held short 19.97M
- Jul 15, 2025: Shares held short 19.55M
- Jul 31, 2025: Shares held short 18.22M
- Aug 15, 2025: Shares held short 13.35M
- Aug 29, 2025: Shares held short 14.71M
- Sep 15, 2025: Shares held short 16.24M
- Sep 30, 2025: Shares held short 17.44M
- Oct 15, 2025: Shares held short 17.85M
- Oct 31, 2025: Shares held short 17.63M
- Nov 14, 2025: Shares held short 15.75M
- Nov 28, 2025: Shares held short 15.97M
- Dec 15, 2025: Shares held short 15.43M
- Dec 31, 2025: Shares held short 16.52M
- Jan 15, 2026: Shares held short 16.88M
- Jan 30, 2026: Shares held short 17.00M
- Feb 13, 2026: Shares held short 17.39M
- Feb 27, 2026: Shares held short 17.02M
- Mar 13, 2026: Shares held short 16.22M
- Mar 31, 2026: Shares held short 16.41M
- Apr 15, 2026: Shares held short 15.74M
- Apr 30, 2026: Shares held short 15.89M
- May 15, 2026: Shares held short 12.36M
- May 29, 2026: Shares held short 12.51M
- Jun 15, 2026: Shares held short 12.81M
- Jun 30, 2026: Shares held short 12.76M
- Jul 15, 2026: Shares held short 10.08M
- Jul 31, 2026: Shares held short 9.22M
- Aug 14, 2026: Shares held short 8.73M
- Aug 31, 2026: Shares held short 8.04M
- Sep 15, 2026: Shares held short 8.06M
- Sep 30, 2026: Shares held short 7.20M
- Oct 15, 2026: Shares held short 8.03M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading25.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 25.4% of the shares in the reported trades were short sales, against 33.8% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 25.4%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 33.8%
- Change
- -8.4 pts
- Short sales a dayon average, of 1.63M shares
- 414.8K
- More than atof 3,674 US-listed companies, same days
- 2%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 34.2%
- Oct 15, 2026: Short sales 40.1%
- Oct 16, 2026: Short sales 53.6%
- Oct 19, 2026: Short sales 32.4%
- Oct 20, 2026: Short sales 29.2%
- Oct 21, 2026: Short sales 25.3%
- Oct 22, 2026: Short sales 32.5%
- Oct 23, 2026: Short sales 37.9%
- Oct 26, 2026: Short sales 39.3%
- Oct 27, 2026: Short sales 38.9%
- Oct 28, 2026: Short sales 28.6%
- Oct 29, 2026: Short sales 28.9%
- Oct 30, 2026: Short sales 22.9%
- Nov 2, 2026: Short sales 30.7%
- Nov 3, 2026: Short sales 40.5%
- Nov 4, 2026: Short sales 37.8%
- Nov 5, 2026: Short sales 18.2%
- Nov 6, 2026: Short sales 24.5%
- Nov 9, 2026: Short sales 26%
- Nov 10, 2026: Short sales 38.8%
- Nov 11, 2026: Short sales 24.9%
- Nov 12, 2026: Short sales 42.9%
- Nov 13, 2026: Short sales 21.3%
- Nov 16, 2026: Short sales 17.4%
- Nov 17, 2026: Short sales 19.8%
- Nov 18, 2026: Short sales 21.9%
- Nov 19, 2026: Short sales 29.6%
- Nov 20, 2026: Short sales 20.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- John Patrick Shannon JrSee RemarksDirectly2.90M
- Kevin McCullochSee RemarksDirectly1.58M
- Steven PieperSee RemarksDirectly1.35M
- Beth HechtSee RemarksDirectly1.09M
- John JohnsonDirectorDirectly683.1K
- Garheng KongDirectorDirectly238.3K
- Jeffrey W ShermanDirectorDirectly219.2K
- Marla PerskyDirectorDirectly157.1K
- Barbara-jean Anne Bormann-kennedyDirectorDirectly126.5K
- James Aloysius BradyDirectorDirectly113.4K
- Dawn HalkuffDirectorDirectly95.0K
- Nerissa KreherDirectorDirectly33.6K
- John P. SchmidDirectorDirectly–
- Menassie TaddeseDirectorDirectly22.4K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| John Patrick Shannon JrSee Remarks | 2.90M | – | Aug 1, 2026 | Form 4 |
| Kevin McCullochSee Remarks | 1.58M | – | Nov 5, 2026 | Form 4 |
| Steven PieperSee Remarks | 1.35M | – | Nov 2, 2026 | Form 4 |
| Beth HechtSee Remarks | 1.09M | – | Nov 2, 2026 | Form 4 |
| John JohnsonDirector | 683.1K | – | Jun 4, 2026 | Form 4 |
| Garheng KongDirector | 238.3K | – | Jun 4, 2026 | Form 4 |
| Jeffrey W ShermanDirector | 219.2K | 5,400 | Aug 28, 2025 | Form 4 |
| Marla PerskyDirector | 157.1K | – | Jun 4, 2026 | Form 4 |
| Barbara-jean Anne Bormann-kennedyDirector | 126.5K | – | Jun 4, 2026 | Form 4 |
| James Aloysius BradyDirector | 113.4K | – | Jun 4, 2026 | Form 4 |
| Dawn HalkuffDirector | 95.0K | – | Jun 4, 2026 | Form 4 |
| Nerissa KreherDirector | 33.6K | – | Jul 1, 2026 | Form 4 |
| John P. SchmidDirector | – | 25.2K | Aug 12, 2024 | Form 4 |
| Menassie TaddeseDirector | 22.4K | – | Nov 2, 2026 | Form 4 |
A lower bound: it counts only the 14 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.31%
- IWCiShares Micro-Cap ETFWeight in the fund0.30%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.08%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.07%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.05%
- IWMiShares Russell 2000 ETFWeight in the fund0.04%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.03%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.02%
18 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 233
- Q4 2025: Managers 226
- Q1 2026: Managers 241
- Q2 2026: Managers 240
Institutional investors by quarter
The fund managers holding XERS, quarter by quarter, from Q2 2018 to Q2 2025, 29 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 240 managers held 108M shares, worth $857M. During the quarter 34 opened a position, 35 closed one, 105 added and 64 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+12%
- D.E. ShawIn the quarter+0.2%
- Vanguard Capital ManagementIn the quarter+5.1%
- State StreetIn the quarter+3.5%
- Geode Capital ManagementIn the quarter+10.0%
- NuveenIn the quarter+50%
- Rosalind AdvisorsIn the quarter-10.0%
- Qube Research & TechnologiesIn the quarter-30%
- Vanguard Portfolio ManagementIn the quarter-1.5%
- Wellington Management GroupIn the quarter+8.9%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 14.53M | +12% | $115M |
| D.E. Shaw | 7.80M | +0.2% | $62M |
| Vanguard Capital Management | 7.34M | +5.1% | $58M |
| State Street | 4.82M | +3.5% | $38M |
| Geode Capital Management | 4.72M | +10.0% | $37M |
| Nuveen | 4.39M | +50% | $35M |
| Rosalind Advisors | 2.91M | -10.0% | $23M |
| Qube Research & Technologies | 2.89M | -30% | $23M |
| Vanguard Portfolio Management | 2.63M | -1.5% | $21M |
| Wellington Management Group | 2.37M | +8.9% | $19M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Xeris Biopharma's filings show?
Who buys and sells is one part of Xeris Biopharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have XERS's insiders bought or sold?
From Jun 2, 2026 to Nov 6, 2026 Xeris Biopharma's insiders bought 0 and sold $3.7M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold XERS?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $76M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.